Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.50 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.48 |
| ▸ | CASP1 | P29466 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2350438 | 0.81 | ELANE (0.50) | ELANEPRTN3ECE1ATM | |
| SCHEMBL2353877 | 0.74 | ELANE (0.72) | ELANEPRTN3CTSKECE1ATM | |
| SCHEMBL2353879 | 0.74 | ELANE (0.72) | ELANEPRTN3CTSKECE1ATM | |
| SCHEMBL5076528 | 0.71 | ELANE (0.67) | ELANEPRTN3CTSKECE1ATM | |
| SCHEMBL6130869 | 0.70 | ELANE (0.63) | ELANEPRTN3ECE1ATM | |
| SCHEMBL2350341 | 0.70 | ELANE (0.52) | ELANEPRTN3 | |
| SCHEMBL2356009 | 0.70 | ELANE (0.52) | ELANEPRTN3ECE1 | |
| SCHEMBL2350988 | 0.70 | ELANE (0.52) | ELANEPRTN3ECE1 | |
| SCHEMBL2353547 | 0.70 | ELANE (0.60) | ELANEPRTN3ECE1 | |
| SCHEMBL2353853 | 0.69 | ELANE (0.51) | ELANEPRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497300-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | Schering Aktiengesellschaft (DE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003080631-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-02 | — | — | WO | disclosed |